Related Experiment Videos
Simvastatin and markers of endothelial function in patients undergoing continuous ambulatory peritoneal dialysis
J Malyszko1, J S Malyszko, T Hryszko
1Department of Nephrology and Internal Medicine, Medical Academy, Bialystok, Poland. jolmal@poczta.onet.pl
Insights
Simvastatin treatment improved lipid profiles and reduced markers of endothelial cell injury in patients with hypercholesterolemia undergoing continuous ambulatory peritoneal dialysis (CAPD). This suggests a potential benefit in slowing atherosclerosis progression and preventing thrombotic complications.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Patients on continuous ambulatory peritoneal dialysis (CAPD) often experience dyslipidemia, increasing cardiovascular death risk.
- Endothelial cell injury is a key factor in atherosclerosis development and thrombotic complications.
Purpose of the Study:
- To evaluate the impact of simvastatin on endothelial cell injury markers in hypercholesterolemic CAPD patients.
- To assess the effects of a 6-month simvastatin regimen on lipid profiles and specific biomarkers.
Main Methods:
- A 6-month open-label study involving 12 hypercholesterolemic CAPD patients.
- Administration of simvastatin 10 mg at bedtime.
- Monitoring of lipid levels and endothelial cell injury markers (VCAM, ICAM, thrombomodulin, vWF, P-selectin, E-selectin).
Main Results:
- Significant reductions in cholesterol and LDL cholesterol within 1 month.
- Significant decreases in vascular cell adhesion molecule (VCAM) and intracellular adhesion molecule (ICAM) at 3 and 6 months, respectively.
- Significant reduction in thrombomodulin after 6 months; vWF, P-selectin, and E-selectin remained unchanged.
Conclusions:
- Simvastatin effectively lowers lipids in CAPD patients.
- Simvastatin favorably influences endothelial function by reducing key adhesion molecules and thrombomodulin.
- This suggests simvastatin may slow atherosclerosis and reduce thrombotic risk in this patient population.
Abstract:
Patients undergoing continuous ambulatory peritoneal dialysis (CAPD) are prone to dyslipidemia and have a high risk of cardiovascular death. The aim of this study was to assess the effects of a 6-month treatment with simvastatin (10 mg at bedtime) on markers of endothelial cell injury in 12 hypercholesterolemic CAPD patients. Cholesterol and low-density lipoprotein cholesterol fell significantly after 1 month of therapy. Simvastatin treatment significantly decreased concentrations of vascular cell adhesion molecule and intracellular adhesion molecule after 3 and 6 months of the therapy, respectively. Thrombomodulin decreased significantly after 6 months of the treatment, whereas von Willebrand's factor, P-selectin and E-selectin remained unaltered during simvastatin therapy. Simvastatin, an effective hypolipemic agent, favorably affects endothelial function and may potentially slow the progression of atherosclerosis and confer protection from thrombotic complications in patients with hypercholesterolemia undergoing CAPD.